Explore
Upload

DocSlides is a free service to upload presentations and documents.

Upload Now

Search Results for 'Olaparib Parp'

Olaparib Parp published presentations and documents on DocSlides.

Store at C Cleaved PARP Asp Antibody Human Specic rev

Store at C Cleaved PARP Asp Antibody Human Specic rev

  • natalia-silvester
  • 1 Slides

022213 Small 100 57525l 10 western blots Large 30...

ParP of SP VincenP’s HospiPal and a CollaNoraPive CenPre of The

ParP of SP VincenP’s HospiPal and a CollaNoraPive CenPre of The

  • min-jolicoeur
  • 100 Slides

Sedation in Palliative Care Presented by: Jennifer...

PCR Application:

PCR Application:

  • alexa-scheidler
  • 25 Slides

Can Breast Cancer be Cured?. Normal, Healthy Cell...

A Cancer

A Cancer

  • stefany-barnette
  • 32 Slides

Knowledge Network. Accelerate . cancer R&D. B...

Service Provider Application

Service Provider Application

  • sherrill-nordquist
  • 100 Slides

NYC Recovers Fiscal Year 201 6 I. OVERVIEW ParP of...

Growth Patterns and Pathobiology of Experimental and

Growth Patterns and Pathobiology of Experimental and

  • pamella-moone
  • 0 Slides

Clinical Malignancies. In Vivo. Updated: March . ...

State of the Art in BRCA

State of the Art in BRCA

  • ellena-manuel
  • 0 Slides

-Mutated Ovarian Cancer. This program will includ...

Case Discussion: Second

Case Discussion: Second

  • celsa-spraggs
  • 0 Slides

Opinion. 55 year-old woman with . recurrent . ova...

The Use of PARP Inhibitors in Breast Cancer: Challenges

The Use of PARP Inhibitors in Breast Cancer: Challenges

  • calandra-battersby
  • 0 Slides

and Opportunities. This program will include a di...

Ovarian cancer update Kentucky cancer Registry

Ovarian cancer update Kentucky cancer Registry

  • danika-pritchard
  • 0 Slides

9/8/2016 . Erica . Takimoto. , D.O., F.A.C.O.O.G....

Updates in Ovarian Cancer Care

Updates in Ovarian Cancer Care

  • tatiana-dople
  • 0 Slides

Lisa McCluskey, MD. Gynecologic Oncologist. June ...

Precision Medicine in the management of gynecologic cancers

Precision Medicine in the management of gynecologic cancers

  • stefany-barnette
  • 0 Slides

Randal West, MD. Ovarian cancer standard of care....

Cancer Chemotherapy Part I: General Cancer Chemotherapy

Cancer Chemotherapy Part I: General Cancer Chemotherapy

  • ellena-manuel
  • 0 Slides

Chapter 16; Pages 797 to 815A. also Section 16.11...

ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP inhibitor,

ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP inhibitor,

  • marina-yarberry
  • 0 Slides

Niraparib. and . Temozolomide. in Patients with...

PARP Inhibitors and Cancer: What Do You Need to Know?

PARP Inhibitors and Cancer: What Do You Need to Know?

  • pasty-toler
  • 0 Slides

This program will include a discussion of off-lab...

The Nurse View: Clinical Considerations in the Management of

The Nurse View: Clinical Considerations in the Management of

  • natalia-silvester
  • 0 Slides

BRCA. -Mutated Advanced Ovarian Cancer. Moderator...

PARP Inhibitors This program will include a discussion of off-label treatment and investigational a

PARP Inhibitors This program will include a discussion of off-label treatment and investigational a

  • conchita-marotz
  • 0 Slides

PARP Inhibitors: What Do We know?. PARP Inhibitor...

PARP and Other DNA Damage Repair Inhibitors in Solid Tumors: An Update

PARP and Other DNA Damage Repair Inhibitors in Solid Tumors: An Update

  • ellena-manuel
  • 0 Slides

Program Overview . Discussion Outline. DNA Repair...

Phase I Study of Olaparib and Temozolomide, in patients with recurrent and/or metastatic Ewing

Phase I Study of Olaparib and Temozolomide, in patients with recurrent and/or metastatic Ewing

  • alexa-scheidler
  • 15 Slides

Phase I Study of Olaparib and Temozolomide, in pa...

ASCO 2019 NSCLC - PARP & Chemotherapy

ASCO 2019 NSCLC - PARP & Chemotherapy

  • mitsue-stanley
  • 12 Slides

ASCO 2019 NSCLC - PARP & Chemotherapy REF Stu...

Phase I Study of Olaparib and Temozolomide, in patients with recurrent and/or metastatic Ewing

Phase I Study of Olaparib and Temozolomide, in patients with recurrent and/or metastatic Ewing

  • karlyn-bohler
  • 15 Slides

Phase I Study of Olaparib and Temozolomide, in pa...

NEw developments IN gynecological Oncology

NEw developments IN gynecological Oncology

  • cheryl-pisano
  • 211 Slides

highlights from the. EUROPEAN . society . of med...

Patient Selection for PARP

Patient Selection for PARP

  • sherrill-nordquist
  • 28 Slides

Inhibitors:. Purpose and Practicalities . Present...

Updates in Ovarian Cancer Care

Updates in Ovarian Cancer Care

  • ellena-manuel
  • 55 Slides

Lisa McCluskey, MD. Gynecologic Oncologist. June ...

Please note, these are the actual video-recorded

Please note, these are the actual video-recorded

  • blindnessinfluenced
  • 27 Slides

proceedings from the live CME event and may includ...

Please note, these are the

Please note, these are the

  • littleccas
  • 21 Slides

actual. . video-recorded proceedings from the . l...

Progress in the Management of Ovarian Cancer: Evolution Over 40 Years

Progress in the Management of Ovarian Cancer: Evolution Over 40 Years

  • medshair
  • 44 Slides

Five-year . survival. 15%. 30%. 40%. ?50%?. First ...

A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician’s choice of therapy

A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician’s choice of therapy

  • bikersjoker
  • 18 Slides

patients with . advanced breast . cancer and a ger...

Policies Procedures and Documents

Policies Procedures and Documents

  • naomi
  • 2 Slides

Course Loads Full-Time and Half-Time DesignationPa...

Genomic Prostate Cancer Testing for Olaparib

Genomic Prostate Cancer Testing for Olaparib

  • abigail
  • 24 Slides

Laura Yarram-Smith . Solid Tumour Lead SWGLH. J...

Arsenic-Induces Dysfunction in Poly(ADP-Ribose) Polymerase-1:

Arsenic-Induces Dysfunction in Poly(ADP-Ribose) Polymerase-1:

  • holly
  • 1 Slides

Arsenic Contamination in Potable Water and an Asse...

GU CONNECT PARP inhibitors in Prostate Cancer

GU CONNECT PARP inhibitors in Prostate Cancer

  • jocelyn
  • 36 Slides

Latest developments. . Prof.. . Neeraj Agarwal, ...

Year in Review Prostate Cancer

Year in Review Prostate Cancer

  • faith
  • 30 Slides

Emmanuel . S . Antonarakis. , MD. Professor of Onc...

1 Svetlana Jeremić 1 , Ana Kesić

1 Svetlana Jeremić 1 , Ana Kesić

  • esther
  • 18 Slides

2. , Jelena Đorović Jovanović. 2. , Biljana Pet...

What Clinicians Want to Know:

What Clinicians Want to Know:

  • violet
  • 51 Slides

Understanding the Factors Affecting the Optimal Di...

Learning Objectives Summarize the latest evidence on poly ADP ribose polymerase (PARP) inhibitors i

Learning Objectives Summarize the latest evidence on poly ADP ribose polymerase (PARP) inhibitors i

  • zen
  • 21 Slides

knowledge. ). Incorporate evidence-based research ...

Copyright © 2024 DocSlides. All Rights Reserved